James retired in 2019 after more than 20 years as Abingworth’s CFO responsible for finance, compliance and administration as well as investment matters, focusing on start-up companies. His directorships have included Avillion, SFJ Pharmaceuticals, Chroma Therapeutics, Clinical Designs and Syntaxin. James has been retained as a Senior Adviser concentrating on clinical co-development deals.
Previously James was CFO of Prolifix, a start-up biotech company. He trained and qualified as a Chartered Accountant with KPMG and holds a degree in Biology with Chemistry from the University of Southampton.